B

BriaCell Therapeutics Corp
D

BCTX

0.59600
USD
-0.00
(-0.60%)
مغلق
حجم التداول
1,468
الربح لكل سهم
0
العائد الربحي
0
P/E
-2
حجم السوق
18,302,958
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CSIQ
    -0.945
    (-5.70%)
    15.645 USD
    E
    ENPH
    -5.460
    (-4.74%)
    109.660 USD
    F
    FSLR
    2.660
    (1.23%)
    218.520 USD
    N
    NOVA
    1.22000
    (17.21%)
    8.31000 USD
    R
    RUN
    -0.050
    (-0.28%)
    17.500 USD
    S
    SEDG
    -2.330
    (-8.07%)
    26.530 USD
    S
    SPWR
    -0.00210
    (-0.25%)
    0.85260 USD
    TSLA
    -15.15
    (-6.53%)
    311.18 USD
    المزيد
الأخبار
المقالات

العنوان: BriaCell Therapeutics Corp

القطاع: Healthcare
الصناعة: Biotechnology
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.